Earth from space

PRESS RELEASE: Orikami Takes Over Multiple Screener From Sanofi

Orikami Contact

PRESS RELEASE: Orikami Takes Over Multiple Screener From Sanofi

· 1 min read

Nijmegen, June 28, 2021

Since June 1, 2021, Orikami is the new owner of The Multiple Screener, a cognitive test for MS developed by Sanofi. A new step in which Orikami continues to build on its ambition to make personalized healthcare possible for as many people as possible. 

“A wonderful deal” – agrees Bram den Teuling, Orikami CEO. “The acquisition of the Multiple Screener is a strategic extension of our portfolio of Digital Biomarkers. It also offers the opportunity to accelerate and expand our services within MS.”

The Multiple Screener was initially developed by Sanofi in collaboration with, among others, the MS Center Amsterdam (Amsterdam UMC, VUmc). The Multiple Screener will initially be used in a large scientific study with various MS centers in the Netherlands, led by Dr. Hanneke Hulst, neuroscientist at MS Center Amsterdam.

Tjerk Balk, Franchise Head, Neurology & Immunology, Sanofi: “The time has come for the next step in the development of the Multiple Screener. There is the confidence that Orikami is the right partner to take this useful app further. In the future, the app will provide insight into cognitive complaints in MS patients in a simple way.”

Who is Orikami?

Orikami is a Dutch eHealth organization specialized in applied data science and the development and implementation of Digital Biomarkers to enable personalized healthcare for people with chronic diseases.

With a team of data scientists and researchers, we are on a mission to improve 100 million lives by 2030 through access to personalized healthcare.